Compare Mesoblast Limited (MESO) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.81B), while Vanguard Intermediate Term Corporate Bond ETF trades at $78.62 (market cap $72.20B). The key difference: Vanguard Intermediate Term Corporate Bond ETF is far larger — about 39.9× Mesoblast Limited's market cap, and Mesoblast Limited is more actively traded (240,620 versus 14,162,206). Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Vanguard Intermediate Term Corporate Bond ETF for 61 Days on average.
| MESO | VCIT | |
|---|---|---|
Market Cap | $1.81B | $72.20B |
Volume | 240,620 | 14,162,206 |
Sector | Health | Fixed Income |
52-Week High | $20.96 | $84.82 |
52-Week Low | $13.19 | $77.98 |
Typical Hold Time | 14 Days | 61 Days |
Enterprise Value | $1.89B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
VCIT trades at $78.27 with minimal daily movement (+0.04%). Technical indicators show a bearish trend with strong selling pressure in moving averages, though oscillators are neutral. The ETF offers a 4.8% yield with a 6-year duration, positioning it as a balanced income option among investment-grade corporate bond ETFs. Recent institutional buying includes Engineers Gate Manager LP's $1.27 million purchase in September 2026.
VCIT presents a compelling risk-return profile for income-focused investors seeking corporate bond exposure. The fund's low 0.03% expense ratio and higher yield compared to treasury alternatives provide value, though interest rate sensitivity and market volatility remain key risks. Analyst sentiment is generally positive given its competitive positioning in the fixed income ETF space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
